A University of Nebraska Medical Center oncologist, Julie Vose, M.D., has been named president-elect of the American Society of Clinical Oncology and will begin her term after ASCO’s annual meeting, which runs from May 30 – June 3 in Chicago.
Dr. Vose will move up to president of the organization in June 2015 and will serve a one-year term as president. With more than 30,000 members, ASCO is the largest organization of clinical oncologists in the world and represents physicians of all oncology specialties who care for people with cancer. Headquartered in Washington, D.C., ASCO is celebrating its 50th anniversary this year.
An expert in lymphoma (cancer of the lymph nodes) and leukemia (cancer of the blood or bone marrow), Dr. Vose is the Neumann M. and Mildred E. Harris Professorial Chair and chief of the oncology/hematology division in the UNMC Department of Internal Medicine. She also serves as associate director of clinical research and co-chair of the lymphoma program at the Fred & Pamela Buffett Cancer Center.
"ASCO is a very diverse and multifaceted organization with so much to offer its membership," Dr. Vose said. "I am excited to serve the ASCO membership as president and to make a difference for oncology professionals and our patients."
Dr. Vose cited the recent enhancements in the society's educational offerings, quality improvement, and broadened advocacy as areas where her experience and training can add to the current ASCO activities, including CancerLinQ(TM), ASCO's groundbreaking health information technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients.
Ken Cowan, M.D., Ph.D., director of the Fred & Pamela Buffett Cancer Center, called the election a great honor for Dr. Vose and UNMC.
"Julie is an internationally recognized leader in clinical trials in lymphoma," he said. "As the leader of the largest organization of clinical oncologists, she will be able to have a major impact on the future directions of clinical research and clinical care in cancer."
Dr. Vose's election and involvement in ASCO and other national oncology organizations are a credit to UNMC as well as Dr. Vose, said James Armitage, M.D., the Joe Shapiro Professor of Internal Medicine in the UNMC Division of Oncology/Hematology.
"I'm incredibly proud of Julie and what she's accomplished," Dr. Armitage said. "This is the most visible and one of the most important oncology positions in the world. It reflects her excellence in clinical medicine and research."
Since joining ASCO in 1991, she has served on the board of directors, as chair of the Cancer Education Committee and Publications Committee, and on a variety of other committees and task forces. She also was a member of the editorial board for the Journal of Clinical Oncology, ASCO’s official journal.
Dr. Vose earneded her undergraduate degree from South Dakota State University, her medical degree from UNMC, and an MBA in health administration from the University of Colorado Business School. She completed her residency and was chief resident in internal medicine and her fellowship in hematology/oncology from UNMC. She joined the UNMC faculty in 1990 as assistant professor, was elevated to associate professor in 1994 and professor in 1998. She has served as chief of oncology/hematology since 2003.
Active in a number of other national organizations, Dr. Vose is co-chair of the Lymphoma Steering Committee for the National Cancer Institute and has served on the U.S. Food and Drug Administration Oncologic Advisory Board. She also served as chair of the Education Committee for both the American Society of Hematology and the American Society of Bone Marrow Transplantation.
Through world-class research and patient care, UNMC generates breakthroughs that make life better for people throughout Nebraska and beyond. Its education programs train more health professionals than any other institution in the state. Learn more at unmc.edu and follow us on social media.
Twitter | Facebook | Pinterest | YouTube